Novartis, Takeda sales and marketing update

Takeda received exclusive rights in Japan to develop and commercialize Novartis' Vaxem-Hib to prevent Haemophilus influenzae type B (Hib) infection. Novartis will manufacture the vaccine, receive ¥100...